PeptideStack

CJC-1295 (With DAC)

Explore the CJC-1295 (With DAC) peptide, a long-acting GHRH analog. Discover its research benefits, mechanism of action, half-life, and side effects.

Research Onlygrowth hormone

Last updated:

Administration
subcutaneous
Origin
Synthetic (GHRH Analog)

Overview

CJC-1295 (With DAC) is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) to extend its half-life. This structural modification allows the CJC-1295 (With DAC) peptide to bind to endogenous serum albumin, significantly prolonging its circulation time compared to standard GHRH. By stimulating the pituitary gland, it promotes a sustained release of growth hormone and insulin-like growth factor 1 (IGF-1), making it a critical tool in research focused on muscle growth, metabolic regulation, and anti-aging therapies.

Potential Benefits

  • Sustained Growth Hormone Release: The addition of the Drug Affinity Complex allows for continuous, prolonged stimulation of the pituitary gland, elevating baseline growth hormone levels for up to a week (Teichman et al., 2006).
  • Increased IGF-1 Levels: By elevating growth hormone, this peptide subsequently drives sustained increases in insulin-like growth factor 1 (IGF-1), which is crucial for cellular repair and tissue regeneration.
  • Enhanced Muscle Hypertrophy: Research indicates that elevated IGF-1 and growth hormone levels facilitate increased protein synthesis, potentially accelerating muscle growth and recovery in animal models.
  • Improved Fat Metabolism: Sustained growth hormone secretion promotes lipolysis, helping researchers investigate the CJC-1295 (With DAC) benefits for targeted fat loss and metabolic optimization.
  • Accelerated Injury Recovery: The peptide's ability to upregulate systemic growth factors makes it a subject of interest for accelerating the healing of musculoskeletal injuries and connective tissue damage.

Where to Buy CJC-1295 (With DAC)

Licensed Peptides

View →

Guru Peptides

View →

These vendors are listed for research reference only. PeptideStack does not endorse, verify, or receive compensation from any vendor. Always verify purity and legitimacy independently.

Side Effects

Common side effects:

  • Injection site reactions including erythema and swelling
  • Transient flushing or warmth post-injection
  • Mild water retention or edema
  • Headaches or dizziness
  • Increased fatigue or lethargy

Rare or serious side effects:

  • Insulin resistance or altered blood glucose levels
  • Carpal tunnel syndrome due to severe fluid retention
  • Pituitary gland hyperstimulation
  • Joint pain or arthralgia

CJC-1295 (With DAC) is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.

Mechanism of Action

Receptor Activation and Hormonal Release define the primary mechanism of the CJC-1295 (With DAC) peptide. It functions as a growth hormone-releasing hormone (GHRH) mimetic, binding selectively to GHRH receptors on the anterior pituitary gland. This binding event triggers a signaling cascade that stimulates the continuous secretion of endogenous growth hormone (GH) without disrupting the body's natural pulsatile release pattern. Consequently, the elevated GH levels stimulate the liver to produce and secrete insulin-like growth factor 1 (IGF-1), which mediates most of the downstream anabolic and metabolic effects. The Drug Affinity Complex (DAC) Technology is what distinguishes this peptide from other GHRH analogs like modified GRF (1-29). The DAC moiety is a reactive maleimidopropionic acid group attached to the peptide chain, which covalently binds to circulating serum albumin immediately upon subcutaneous injection. This bioconjugation protects the peptide from rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-IV), extending its half-life from mere minutes to approximately 6 to 8 days, thereby allowing for steady-state hormonal elevation with infrequent dosing.

Origin & History

Discovery and Development of CJC-1295 (With DAC) was spearheaded by ConjuChem Biotechnologies in the early 2000s. Researchers sought to overcome the extremely short half-life of natural GHRH and its early synthetic counterparts, which required multiple daily injections to maintain therapeutic efficacy. By applying their proprietary Drug Affinity Complex technology, scientists successfully created a bioconjugated peptide that maintained receptor affinity while drastically improving pharmacokinetic stability. Early clinical trials demonstrated its profound ability to elevate GH and IGF-1 levels in healthy human subjects for extended periods. Regulatory Status and Clinical Trajectory have shifted since its initial development phase. Although early phase II clinical trials investigated its potential for treating lipodystrophy and growth hormone deficiency, development was eventually halted following reports of adverse events in specific patient populations. Today, the peptide remains strictly classified as a research-only chemical. It is not approved by the FDA for human consumption, and ongoing studies primarily focus on understanding the long-term CJC-1295 (With DAC) side effects and its physiological impact in controlled laboratory settings.

Frequently Asked Questions

Related Peptides

Ipamorelin

Research Only

Discover the science behind the Ipamorelin peptide. Explore its research-backed benefits for bone density, body composition, and gastrointestinal function.